An observational study in Anaphylaxis, sponsored by Charite University, Berlin, Germany. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2024-08-21.
Sponsored by Charite University, Berlin, Germany · Observational
The Anaphylaxis Registry aims to assess data in a standardized form about symptoms, triggers, cofactors and therapy management from patients who experienced an anaphylactic reaction. This should improve diagnosis and long-term management of these life-threatening allergic reactions.
A better understanding of the triggers and pathology of anaphylactic reactions could lead to a better diagnosis and prophylaxis to avoid the occurence of these life-threatening allergic reactions. This can be an advantage for affected persons regarding the their treatment and long-term management.
The Anaphylaxis Registry is an opportunity to gather these standardized data. The blood sampling is optional for the patient, however, it will contribute to the better understanding of the sensitization profile and possible mechanisms. Recent publications showed a correlation between an anaphylactic reaction and certain biomarkers. Those data will be validated in a larger number of population with identification of further biomarkers. It is presumed that certain genetic and epigenetic polymorphisms are abundant for patients who experienced an anaphylaxis.
To summarize, this study aims to contribute to a better understanding of the anaphylaxis in general, the diagnosis, and the prognosis with different severities. With the identification of a certain trigger, the obtained understanding may help to decrease the risk of or prevent future repeating reactions.
100 studies on the registry are indexed under Anaphylaxis; 20 are open to participants now.
This study's planned enrollment of 20,000 is above the median of 137 across 48 observational studies indexed under Anaphylaxis.
Browse Anaphylaxis studies →Charite University, Berlin, Germany is the lead sponsor of 857 studies on the registry; 129 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Subjects who experienced a severe anaphylactic reaction and presenting in a participating center
Exclusion Criteria:
-
Patients who experienced an anaphylactic reaction will be observed
Other: not applicable, observational study
Patients do not receive intervention; observational study
Influence of risk factors
Correlation between risk factors (age, epiphenomenon, comorbidity) and severity of anaphylaxis
Time frame: 10 years
Epiphenomenon
Correlation between epiphenomenoa of the anaphylaxis and the frequency of allergic reactions
Time frame: 10 years
Current use of adrenaline
Assessment of acute treatments with adrenaline
Time frame: 10 years
Future use of adrenaline
Comparison of the frequencies of the use of adrenaline from beginning to end of the observation
Time frame: 10 years
Country-specific differences in anaphylaxis handling
Comparison of the triggers, diagnosis, treatment and prophylaxis of anaphylactic reactions throughout different countries
Time frame: 10 years
Biomarkers
Identification of biomarkers (e.g. PGE2 via ELISA, Tryptase via ImmunoCAP) for anaphylactic reactions
Time frame: 10 years
Epigenetics
Correlation of genetic and epigenetic factors with the pathogenesis of severe allergic reactions
Time frame: 10 years
Plan to share: Undecided
No publications or documents are linked to this record.
Started Jan 2007 (actual). Primary completion is estimated for Dec 2030, 287 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Charite University, Berlin, Germany →